This novel agent has a dual mechanism ... to MDM2–p53 blockade. Over the past 20 years, many advances in cancer treatment have provided benefit to patients; however, there remain multiple ...

MDM2, on the other hand, is one of the most frequently studied oncogenes and is an excellent target for cancer therapy, based on its p53-dependent and p53-independent oncogenic activities in ...